Acute Liver Failure Market Players:
- Ipsen
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Gilead Sciences, Inc.
- Pfizer Inc.
- Novartis AG
- Bristol Myers Squibb
- AbbVie Inc.
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Zydus Pharmaceuticals Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of acute liver failure is assessed at USD 28.11 billion.
The global acute liver failure market size was valued at more than USD 26.69 billion in 2025 and is expected to register a CAGR of over 5.9%, exceeding USD 47.35 billion revenue by 2035.
By 2035, North America in the acute liver failure market is projected to command a 37% share, supported by an unhealthy lifestyle causing obesity.
Key players in the market include Ipsen, Gilead Sciences, Inc., Pfizer Inc., Novartis AG, Bristol Myers Squibb, AbbVie Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, Zydus Pharmaceuticals Inc.
